
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Eytan Stein, MD, discusses the AUGMENT-101 trial and menin inhibition in patients with MLL-rearranged and NPM1 mutant acute leukemia, which was presented at the 63rd ASH Annual Meeting in 2021.
OncLive® Rapid Readout from Safety and Efficacy of Menin Inhibition in Patients with MLL-Rearranged and NPM1 Mutant Acute Leukemia: SNDX-5613
Segment Description: Eytan Stein, MD, discusses the AUGMENT-101 trial and menin inhibition in patients with MLL-rearranged and NPM1 mutant acute leukemia, which was presented at the 63rd ASH Annual Meeting in 2021. (
Segment Body Content:
Methods
Results
Conclusions






